Natural History of Metabolic Dysfunction-Associated Steatotic Liver Disease: From Metabolic Syndrome to Hepatocellular Carcinoma
<i>Introduction</i>: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) stems from disrupted lipid metabolism in the liver, often linked to obesity, type 2 diabetes, and dyslipidemia. In Mexico, where obesity affects 36.9% of adults, MASLD prevalence has risen, especially w...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-01-01
|
| Series: | Medicina |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1648-9144/61/1/88 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832588010172973056 |
|---|---|
| author | Melchor Alpízar Salazar Samantha Estefanía Olguín Reyes Andrea Medina Estévez Julieta Alejandra Saturno Lobos Jesús Manuel De Aldecoa Castillo Juan Carlos Carrera Aguas Samary Alaniz Monreal José Antonio Navarro Rodríguez Dulce María Fernanda Alpízar Sánchez |
| author_facet | Melchor Alpízar Salazar Samantha Estefanía Olguín Reyes Andrea Medina Estévez Julieta Alejandra Saturno Lobos Jesús Manuel De Aldecoa Castillo Juan Carlos Carrera Aguas Samary Alaniz Monreal José Antonio Navarro Rodríguez Dulce María Fernanda Alpízar Sánchez |
| author_sort | Melchor Alpízar Salazar |
| collection | DOAJ |
| description | <i>Introduction</i>: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) stems from disrupted lipid metabolism in the liver, often linked to obesity, type 2 diabetes, and dyslipidemia. In Mexico, where obesity affects 36.9% of adults, MASLD prevalence has risen, especially with metabolic syndrome affecting 56.31% by 2018. MASLD can progress to Metabolic Dysfunction-Associated Steatohepatitis (MASH), affecting 5.27% globally, leading to severe complications like cirrhosis and hepatocellular carcinoma. <i>Background</i>: Visceral fat distribution varies by gender, impacting MASLD development due to hormonal influences. Insulin resistance plays a central role in MASLD pathogenesis, exacerbated by high-fat diets and specific fatty acids, leading to hepatic steatosis. Lipotoxicity from saturated fatty acids further damages hepatocytes, triggering inflammation and fibrosis progression in MASH. Diagnosing MASLD traditionally involves invasive liver biopsy, but non-invasive methods like ultrasound and transient elastography are preferred due to their safety and availability. These methods detect liver steatosis and fibrosis with reasonable accuracy, offering alternatives to biopsy despite varying sensitivity and specificity. <i>Conclusions</i>: MASLD as a metabolic disorder underscores its impact on public health, necessitating improved awareness and early management strategies to mitigate its progression to severe liver diseases. |
| format | Article |
| id | doaj-art-a9b2c03384eb456aaefd4325d780774d |
| institution | Kabale University |
| issn | 1010-660X 1648-9144 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Medicina |
| spelling | doaj-art-a9b2c03384eb456aaefd4325d780774d2025-01-24T13:40:33ZengMDPI AGMedicina1010-660X1648-91442025-01-016118810.3390/medicina61010088Natural History of Metabolic Dysfunction-Associated Steatotic Liver Disease: From Metabolic Syndrome to Hepatocellular CarcinomaMelchor Alpízar Salazar0Samantha Estefanía Olguín Reyes1Andrea Medina Estévez2Julieta Alejandra Saturno Lobos3Jesús Manuel De Aldecoa Castillo4Juan Carlos Carrera Aguas5Samary Alaniz Monreal6José Antonio Navarro Rodríguez7Dulce María Fernanda Alpízar Sánchez8Endocrinology, Specialized Center for Diabetes, Obesity and Prevention of Cardiovascular Diseases (CEDOPEC), Mexico City 11650, MexicoClinical Research, Specialized Center for Diabetes, Obesity and Prevention of Cardiovascular Diseases (CEDOPEC), Mexico City 11650, MexicoClinical Research, Specialized Center for Diabetes, Obesity and Prevention of Cardiovascular Diseases (CEDOPEC), Mexico City 11650, MexicoClinical Research, Specialized Center for Diabetes, Obesity and Prevention of Cardiovascular Diseases (CEDOPEC), Mexico City 11650, MexicoClinical Nutrition, Specialized Center for Diabetes, Obesity and Prevention of Cardiovascular Diseases (CEDOPEC), Mexico City 11650, MexicoClinical Nutrition, Specialized Center for Diabetes, Obesity and Prevention of Cardiovascular Diseases (CEDOPEC), Mexico City 11650, MexicoClinical Research, Specialized Center for Diabetes, Obesity and Prevention of Cardiovascular Diseases (CEDOPEC), Mexico City 11650, MexicoClinical Research, Specialized Center for Diabetes, Obesity and Prevention of Cardiovascular Diseases (CEDOPEC), Mexico City 11650, MexicoClinical Research, Specialized Center for Diabetes, Obesity and Prevention of Cardiovascular Diseases (CEDOPEC), Mexico City 11650, Mexico<i>Introduction</i>: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) stems from disrupted lipid metabolism in the liver, often linked to obesity, type 2 diabetes, and dyslipidemia. In Mexico, where obesity affects 36.9% of adults, MASLD prevalence has risen, especially with metabolic syndrome affecting 56.31% by 2018. MASLD can progress to Metabolic Dysfunction-Associated Steatohepatitis (MASH), affecting 5.27% globally, leading to severe complications like cirrhosis and hepatocellular carcinoma. <i>Background</i>: Visceral fat distribution varies by gender, impacting MASLD development due to hormonal influences. Insulin resistance plays a central role in MASLD pathogenesis, exacerbated by high-fat diets and specific fatty acids, leading to hepatic steatosis. Lipotoxicity from saturated fatty acids further damages hepatocytes, triggering inflammation and fibrosis progression in MASH. Diagnosing MASLD traditionally involves invasive liver biopsy, but non-invasive methods like ultrasound and transient elastography are preferred due to their safety and availability. These methods detect liver steatosis and fibrosis with reasonable accuracy, offering alternatives to biopsy despite varying sensitivity and specificity. <i>Conclusions</i>: MASLD as a metabolic disorder underscores its impact on public health, necessitating improved awareness and early management strategies to mitigate its progression to severe liver diseases.https://www.mdpi.com/1648-9144/61/1/88Metabolic Dysfunction-Associated Steatotic Liver Diseasesteatohepatitisliver cirrhosiscarcinoma hepatocellularelastography |
| spellingShingle | Melchor Alpízar Salazar Samantha Estefanía Olguín Reyes Andrea Medina Estévez Julieta Alejandra Saturno Lobos Jesús Manuel De Aldecoa Castillo Juan Carlos Carrera Aguas Samary Alaniz Monreal José Antonio Navarro Rodríguez Dulce María Fernanda Alpízar Sánchez Natural History of Metabolic Dysfunction-Associated Steatotic Liver Disease: From Metabolic Syndrome to Hepatocellular Carcinoma Medicina Metabolic Dysfunction-Associated Steatotic Liver Disease steatohepatitis liver cirrhosis carcinoma hepatocellular elastography |
| title | Natural History of Metabolic Dysfunction-Associated Steatotic Liver Disease: From Metabolic Syndrome to Hepatocellular Carcinoma |
| title_full | Natural History of Metabolic Dysfunction-Associated Steatotic Liver Disease: From Metabolic Syndrome to Hepatocellular Carcinoma |
| title_fullStr | Natural History of Metabolic Dysfunction-Associated Steatotic Liver Disease: From Metabolic Syndrome to Hepatocellular Carcinoma |
| title_full_unstemmed | Natural History of Metabolic Dysfunction-Associated Steatotic Liver Disease: From Metabolic Syndrome to Hepatocellular Carcinoma |
| title_short | Natural History of Metabolic Dysfunction-Associated Steatotic Liver Disease: From Metabolic Syndrome to Hepatocellular Carcinoma |
| title_sort | natural history of metabolic dysfunction associated steatotic liver disease from metabolic syndrome to hepatocellular carcinoma |
| topic | Metabolic Dysfunction-Associated Steatotic Liver Disease steatohepatitis liver cirrhosis carcinoma hepatocellular elastography |
| url | https://www.mdpi.com/1648-9144/61/1/88 |
| work_keys_str_mv | AT melchoralpizarsalazar naturalhistoryofmetabolicdysfunctionassociatedsteatoticliverdiseasefrommetabolicsyndrometohepatocellularcarcinoma AT samanthaestefaniaolguinreyes naturalhistoryofmetabolicdysfunctionassociatedsteatoticliverdiseasefrommetabolicsyndrometohepatocellularcarcinoma AT andreamedinaestevez naturalhistoryofmetabolicdysfunctionassociatedsteatoticliverdiseasefrommetabolicsyndrometohepatocellularcarcinoma AT julietaalejandrasaturnolobos naturalhistoryofmetabolicdysfunctionassociatedsteatoticliverdiseasefrommetabolicsyndrometohepatocellularcarcinoma AT jesusmanueldealdecoacastillo naturalhistoryofmetabolicdysfunctionassociatedsteatoticliverdiseasefrommetabolicsyndrometohepatocellularcarcinoma AT juancarloscarreraaguas naturalhistoryofmetabolicdysfunctionassociatedsteatoticliverdiseasefrommetabolicsyndrometohepatocellularcarcinoma AT samaryalanizmonreal naturalhistoryofmetabolicdysfunctionassociatedsteatoticliverdiseasefrommetabolicsyndrometohepatocellularcarcinoma AT joseantonionavarrorodriguez naturalhistoryofmetabolicdysfunctionassociatedsteatoticliverdiseasefrommetabolicsyndrometohepatocellularcarcinoma AT dulcemariafernandaalpizarsanchez naturalhistoryofmetabolicdysfunctionassociatedsteatoticliverdiseasefrommetabolicsyndrometohepatocellularcarcinoma |